Together Pharma

Together Pharma Equity

The The Equity of Together Pharma (TGTR.TA) as of Oct 8, 2026 is 33.32 M ILS. In the previous year, The Equity was -7.79 M ILS — a change of -527.61% (higher).

Equity

33.32 MILS

YoY

-527.61%

Last updated:

In 2024, Together Pharma's equity was 33.32 M ILS, a -527.61% increase from the -7.79 M ILS equity in the previous year.

The Together Pharma Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
-174,500.00 ILS
Jan 1, 2018
-29.75 M ILS
Jan 1, 2019
-10.86 M ILS
Jan 1, 2020
8.29 M ILS
Jan 1, 2021
20.63 M ILS
Jan 1, 2022
-426,000.00 ILS
Jan 1, 2023
-7.79 M ILS
Jan 1, 2024
33.32 M ILS
The Together Pharma Equity history
YEAREquityYoY
33.32 MILS-527.61%
-7.79 MILS+1,729.34%
-426,000.00ILS-102.07%
20.63 MILS+148.86%
8.29 MILS-176.30%
-10.86 MILS-63.49%
-29.75 MILS+16,950.43%
-174,500.00ILS-113.38%
1.30 MILS-67.45%
4.01 MILS-714.10%
-652,400.00ILS—
Access this data via the Eulerpool API
Get Free API Key

Together Pharma Stock analysis

What does Together Pharma do? Together Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Together Pharma's Equity

Together Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Together Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Together Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Together Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Together Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Together Pharma stock

The Equity of Together Pharma is 33.32 M ILS in 2024.

The Equity of Together Pharma changed from -7.79 M ILS to 33.32 M ILS, representing a -527.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Together Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Together Pharma historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Together Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Together Pharma